Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15399
|
| Title: | Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs |
| Other Titles: | Pretreatment γ-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs |
| Authors: | Jang, TY;Liang, PC;Jun, DW;Jung, JH;Toyoda, H;Wang, CW;Yuen, MF;Cheung, KS;Yasuda, S;Kim, SE;Yoon, EL;An, J;Enomoto, M;Kozuka, R;Chuma, M;Nozaki, A;Ishikawa, T;Watanabe, T;Atsukawa, M;Arai, T;Hayama, K;Ishigami, M;Cho, YK;Ogawa, E;Kim, HS;Shim, JJ;Uojima, H;Jeong, SW;Ahn, SB;Takaguchi, K;Senoh, T;Buti, M;Vargas-Accarino, E;Abe, H;Takahashi, H;Inoue, K;Huang, JF;Chuang, WL;Yeh, ML;Dai, CY;Huang, CF;Nguyen, MH;Yu, ML |
| Contributors: | NHRI Graduate Student Program |
| Abstract: | Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month-6) after initiating NAs were measured to explore their association with all-cause, liver-related, and non-liver-related mortality. The annual incidence of all-cause mortality was 0.9/100 person-years over a follow-up period of 17,436.3 person-years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p = 0.002) and Month-6-GGT levels (62.1 vs. 38.4 U/L, p < 0.001). The factors associated with all-cause mortality included cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92-3.70, p < 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003-1.006, p < 0.001), alanine aminotransferase level (HR/CI: 0.996/0.994-0.998, p = 0.001), and age (HR/CI: 1.06/1.04-1.07, p < 0.001). Regarding liver-related mortality, the independent factors included cirrhosis (HR/CI: 4.36/2.79-6.89, p < 0.001), pretreatment GGT levels (HR/CI: 1.006/1.004-1.008, p < 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990-0.997, p = 0.001), age (HR/CI: 1.03/1.01-1.05, p < 0.001), and fatty liver disease (HR/CI: 0.30/0.15-0.59, p = 0.001). Pretreatment GGT levels were also independently predictive of non-liver-related mortality (HR/CI: 1.003/1.000-1.005, p = 0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose-dependent manner of <25, 25-75, and >75 percentile of pretreatment GGT levels was observed with respect to the all-cause mortality (trend p < 0.001). Pretreatment serum GGT levels predicted all-cause, liver-related, and non-liver-related mortality in patients with CHB treated with NAs. |
| Date: | 2024-02 |
| Relation: | Kaohsiung Journal of Medical Sciences. 2024 Feb;40(2):188-197. |
| Link to: | http://dx.doi.org/10.1002/kjm2.12771 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1607-551X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001096107200001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85175006795 |
| Appears in Collections: | [其他] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB37885338.pdf | | 1792Kb | Adobe PDF | 129 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
